- The risk we bear: the effects of review speed and industry user fees on new drug safetyMary K Olson
Department of Economics, Tulane University, 6823 St Charles Avenue, New Orleans, LA 70118 5698, USA
J Health Econ 27:175-200. 2008..Although any increase in risks must be weighed against benefits, the results show a trade-off between review speed and drug safety...
- Managing delegation in the FDA: reducing delay in new-drug reviewMary K Olson
Yale University, USA
J Health Polit Policy Law 29:397-430. 2004..The results suggest that the user fee reform has helped politicians manage delegation and reduce delay in new-drug review...
- Explaining reductions in FDA drug review times: PDUFA mattersMary K Olson
Yale University, New Haven, Connecticut, USA
Health Aff (Millwood) . 2003..She also found that there was little reduction in drug review times until after user fees were introduced...
- Are novel drugs more risky for patients than less novel drugs?Mary K Olson
School of Public Health, Yale University, New Haven, CT 06520, USA
J Health Econ 23:1135-58. 2004..These results suggest that novel drugs pose greater risk of serious ADRs for patients relative to less novel drugs...